Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Aug 16, 2026 | Seeking Alpha | Seeking Alpha ContributorSeeking Alpha | Johnson & Johnson $JNJ• NYSE | PharmaceuticalsPharmaceuticals | Johnson & Johnson Johnson & Johnson has shown strong performance in 2026, with shares up 28% total return, outperforming the S&P 500 and the Health Care Sector ETF. Despite ... | NEUTRAL | View Pitch → |
| Jan 27, 2026 | Fund Letter | Brian Woglom, Paul Howanitz, Kevin ToneyAmerican Century Equity Income Fund | Johnson & Johnson $JNJ• NYSE | PharmaceuticalsPharmaceuticals | American Century Equity Income Fund 2025 Q4 (JNJ) Johnson & Johnson. This pharmaceutical and... | BULL | View Pitch → |
| Jan 27, 2026 | Fund Letter | Silas Myers, Brian MasseyMar Vista US Quality | Johnson & Johnson $JNJ• NYSE | PharmaceuticalsPharmaceuticals | Mar Vista US Quality 2025 Q4 (JNJ) Johnson & Johnson (JNJ) stock demonstrated strong performance in Q4, driven by robust financial results, upward guidance revisions, and accelerating growth for the pharmaceutical and medical technology segments. The company's consistent... | BULL | View Pitch → |
| Jan 20, 2026 | Fund Letter | Ariel Investments, LLCAriel Focus Fund | Johnson & Johnson $JNJ• NYSE | PharmaceuticalsPharmaceuticals | Ariel Focus Fund 2025 Q4 (JNJ) Additionally, consumer healthcare company, Johnson & Johnson (JNJ) traded up on strong earnings and a raise in full-year revenue guidance. With a sharpened... | BULL | View Pitch → |
| Nov 28, 2025 | Fund Letter | ArrowMark Colorado Holdings LLCMeridian Hedged Equity Fund | Johnson & Johnson $JNJ• NYSE | PharmaceuticalsPharmaceuticals | Meridian Hedged Equity Fund 2025 Q3 (JNJ) Johnson & Johnson is a major healthcare company focused on innovative pharmaceuticals and medical devices. The company faces... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.